FDA staff backs Acadia's drug to treat psychosis associated with Parkinson's disease
March 25 (Reuters) - U.S. Food and Drug Administration staff members said on Friday Acadia Pharmaceuticals Inc's drug to treat psychosis associated with Parkinson's disease was effective enough to warrant approval.
No comments:
Post a Comment